
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

Details : COPIKTRA (duvelisib) is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first US approved dual inhibitor of PI3K-delta and PI3K-gamma, two enzymes known to help support the growth and survival of malignant cells.
Product Name : Copiktra
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 09, 2023

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BMS-986345
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Moffitt Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Details : BMS-986345 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, Non-Hodgkin.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
October 04, 2021
Lead Product(s) : BMS-986345
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Moffitt Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
Details : Duvelisib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 27, 2021

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Duvelisib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : COPIKTRA is an oral dual inhibitor of the PI3K-delta and gamma pathways, which are involved in the proliferation, growth, and migration of malignant cells and are thought to play a role in the formation and maintenance of a supportive tumor microenvironm...
Product Name : Copiktra
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 01, 2021
Lead Product(s) : Duvelisib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : John Kirkwood
Deal Size : Inapplicable
Deal Type : Inapplicable
Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
Details : Nivolumab is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Melanoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 30, 2020
Lead Product(s) : Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : John Kirkwood
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Duvelisib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Verastem Oncology
Deal Size : $481.0 million
Deal Type : Divestment
Verastem Oncology Announces Closing of COPIKTRA® (duvelisib) Sale to Secura Bio
Details : Verastem’s sale of COPIKTRA to Secura Bio follows Verastem’s previously announced new strategic direction focused on development of its RAF/MEK inhibitor (VS-6766) and FAK inhibitor (defactinib) program in KRAS mutant (KRASmt) solid tumors.
Product Name : Copiktra
Product Type : Miscellaneous
Upfront Cash : $70.0 million
September 30, 2020
Lead Product(s) : Duvelisib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Verastem Oncology
Deal Size : $481.0 million
Deal Type : Divestment

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Duvelisib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Verastem Oncology
Deal Size : $311.0 million
Deal Type : Divestment
Verastem Oncology Signs Definitive Agreement to Sell COPIKTRA® (duvelisib) Rights to Secura Bio
Details : Verastem’s sale of COPIKTRA follows the Company’s previously announced strategic direction to focus on maximizing the broad potential of its RAF/MEK inhibitor (VS-6766) and FAK inhibitor (defactinib) program in KRAS mutant (KRASmt) solid tumors.
Product Name : Copiktra
Product Type : Miscellaneous
Upfront Cash : $70.0 million
August 10, 2020
Lead Product(s) : Duvelisib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Verastem Oncology
Deal Size : $311.0 million
Deal Type : Divestment

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Duvelisib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Dana-Farber Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
Details : Duvelisib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 23, 2018
Lead Product(s) : Duvelisib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Dana-Farber Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Duvelisib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Dana-Farber Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
Details : IPI-145 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 06, 2014
Lead Product(s) : Duvelisib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Dana-Farber Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Abdullah Kutlar
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Details : Panobinostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anemia, Sickle Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 22, 2010
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Abdullah Kutlar
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All